TXG - 10x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
- 10x Genomics ( NASDAQ: TXG ) said that it expects Q2 2022 revenue to be ~$114.5M , below the consensus estimate of $127.67M.
- That's a 1% decrease from the year-ago period.
- Shares are down 13% in after-hours trading.
- While year-over-year revenue increased in the Americas, it declined in Europe and the Asia Pacific region.
- The company also said that Jim Wilbur will join the company as chief commercial officer on July 27. He was previously at Meso Scale Discovery.
For further details see:
10x Genomics guides to Q2 revenues below consensus; shares down 13% after hours